ClinicalTrials.gg
RecruitingNCT07359157CLCO-9Updated Aug 12, 2026

Changing Lives and Changing Outcomes-9 at Worcester Recovery Center and Hospital

An interventional study of Changing Lives and Changing Outcomes-9 in Serious Mental Illness, Psychotic Disorder and Depression, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Psychotic Disorders by Massachusetts General Hospital — 4 open to participants now, 6 under way, none of them phase 3. Psychotic Disorders · Massachusetts General Hospital.

Planned enrollment
11th of 15
40 · median 65
Started
2026
the only one that year
No phase
9 of 15
4 open now
Registered
15th of 15
by date

Among the 15 studies in Psychotic Disorders by Massachusetts General Hospital, this one is the 11th largest by planned enrollment, is the only one that started in 2026, is one of 9 with no phase, and was the 15th registered.

Psychotic Disorders

1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.

Browse Psychotic Disorders studies →

Open to participants now

4 of the 15 studies in Psychotic Disorders by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Psychotic Disorders by Massachusetts General Hospital, or all of them as a file.
02

Study summary

People with serious mental illness (depression, bipolar, and schizophrenia spectrum disorders) have high rates of repeated criminal legal involvement and psychiatric hospitalizations. Longstanding research shows that in addition to treating clients' symptoms of mental illness, targeting risk factors for legal involvement can help reduce their chances of future incarcerations. Because hospitals are becoming increasingly forensic, treatment programs that address both mental illness and risk factors for legal involvement may be especially helpful in a state hospital setting, like Worcester Recovery Center and Hospital (WRCH). This treatment study offers an adjunctive 9-session intervention, Changing Lives and Changing Outcomes-9 (CLCO-9), for patients at WRCH; this program is designed to help people with serious mental illness who are involved in the legal system increase their awareness of their mental health and reduce their chances of future legal involvement.

The investigators are proposing a treatment study testing the use of the CLCO-9 group intervention with patients with serious mental illness with current or previous criminal legal involvement at Worcester Recovery Center and Hospital (WRCH). The study has three aims:

  1. Evaluate feasibility, fidelity, and patient satisfaction during the implementation of the CLCO-9 group treatment at WRCH
  2. Evaluate CLCO-9's effectiveness on improving patient's self-reported mental health, and behavioral indicators of mental health and risk factors for legal involvement
  3. Explore changes in WRCH clinicians' knowledge and attitudes about treating risk factors for criminal legal involvement.

To test these aims, the research team will employ a two-phase study. In the first phase, the researchers will implement the intervention and make necessary adjustments to maximize the success of the implementation. In the second phase, the researchers will evaluate the treatment program's effectiveness in producing change from pre- to post-treatment.

All patient participants in this study will receive the intervention. The projected sample size is about 20 treatment completers and 4 to 8 group leaders.

Read the detailed description

In this treatment study, the investigators propose to implement and evaluate a 9-session intervention, cognitive-behavioral intervention, Changing Lives and Changing Outcomes-9 (CLCO-9), for patients at Worcester Recovery Center and Hospital (WRCH) with serious mental illness (i.e., depression, bipolar, and psychotic disorders) with current or previous legal involvement.

The CLCO-9 groups will be led by WRCH clinical staff/trainees who have competed a clinical training in the CLCO-9 intervention led by Dr. Scanlon (PI). This study is comprised of two parts: a clinical phase, and then the effectiveness phase (see Section 5.7 Study Procedures). The study is guided by the following aims:

Aim 1 will evaluate feasibility, fidelity, and patient satisfaction during the implementation of the CLCO-9 group treatment at WRCH.

The researchers hypothesize the implementation will demonstrate feasibility based on the number of patients who agree to join the group and attendance. The researchers anticipate approximately 40 patients will agree to participate in the study, with a projected sample size of 20 treatment completers (i.e., patient participants who attended 5 or more of the 9 group sessions and post-treatment measures). Using transcriptions from consultation calls with group leaders on clinical and implementation issues, the research team will also explore barriers and facilitators of the intervention's feasibility.

The researchers hypothesize that group leader participants will report high levels of session fidelity to the treatment program per session fidelity checklists (i.e., ≥ 75% of session content covered, on average, per session).

The researchers hypothesize patient participants will report satisfaction with CLCO-9 treatment sessions (per the Client Satisfaction Questionnare-8).

The researchers will also explore patient engagement in each session, per group leader participant report on a scale of 1 (disengaged) to 5 (exemplary). The research team will collect patients' session homework to explore homework completion as another indicator of engagement.

Aim 2 will evaluate the CLCO-9's effectiveness in improving patient-reported and behavioral indicators of mental health and criminal risk.

From pre-to post-treatment, the researchers hypothesize improvements in patient-reported emotional distress (per the Modified Colorado Symptom Index), aggression and hostility (per the Bus-Perry Aggression Questionnaire), criminal thinking (per the Psychological Inventory of Criminal Thinking Styles-Short Form), antisocial attitudes (per the Measure of Criminal Attitudes and Associates Part B), and knowledge of treatment content (per the CLCO-9 knowledge quiz) will improve from pre- to post-treatment.

The investigators hypothesize that, per WRCH chart review, behavioral outcomes will show reduced Broset Violence Checklist scores and fewer restraints/seclusions from before to immediately after treatment. The research team also hypothesizes treatment recipients will show improved treatment engagement (i.e., attending more treatment meetings and other groups) across treatment.

Aim 3 will evaluate the changes in WRCH CLCO-9 clinician knowledge and attitudes about treating criminal risk.

The investigators hypothesize that clinicians will show increased knowledge (per the Knowledge about Addressing Criminal Risk quiz) and attitudes (per the Staff Responses to Attitude scale) on addressing criminal risk among patients with SMI after leading the CLCO-9 groups. Change will be calculated by comparing pre-training survey data, post-training survey data, and follow-up survey data after group leaders complete their first and last groups.

03

Conditions studied

  • Serious Mental Illness
  • Psychotic Disorder
  • Depression
  • Bipolar

Keywords

  • serious mental illness
  • criminogenic risk
  • criminal legal involvement
  • treatment
  • forensic
  • state hospital
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Currently hospitalized at Worcester Recovery Center and Hospital (WRCH)
  • At least 18 years old
  • Self-reported current or past legal involvement
  • Speaks English
  • For patients without a legally authorized representative (LAR): demonstrate capacity to consent per the Capacity Assessment Record (CAR).
  • For patients with an LAR: assent to participate.

Exclusion criteria

Exclusion Criteria:

  • Hospital status that does not permit group attendance (e.g., room-based seclusion)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Changing Lives and Changing Outcomes-9 Group

    Changing Lives and Changing Outcomes-9, a brief cognitive-behavioral therapy intervention for people with mental illness involved in the legal system, will be administered in treatment groups consistent with standard programming at the state hospital. Patients will be able to participate in this group in addition to any other services at the hospital.

    Behavioral: Changing Lives and Changing Outcomes-9

Interventions

  • BehavioralChanging Lives and Changing Outcomes-9

    A brief, cognitive therapy-based intervention for people with mental illness and legal system involvement.

    Also known as: CLCO-9

06

What researchers measure

Primary outcomes

  1. Buss-Perry Aggression Questionnaire

    aggression and hostility

    Time frame: From before starting treatment (baseline assessment) to after completing treatment (anticipated to be about 7 weeks after starting treatment)

  2. Modified Colorado Symptom Index

    emotional distress

    Time frame: From before starting treatment (baseline assessment) to after completing treatment (anticipated to be about 7 weeks after starting treatment)

  3. Psychological Inventory of Criminal Thinking Styles-Short Form

    criminal thinking

    Time frame: From before starting treatment (baseline assessment) to after completing treatment (anticipated to be about 7 weeks after starting treatment)

  4. Measure of Criminal Attitudes and Associates

    antisocial attitudes

    Time frame: From before starting treatment (baseline assessment) to after completing treatment (anticipated to be about 7 weeks after starting treatment)

  5. CLCO-9 knowledge quiz

    treatment content

    Time frame: From before starting treatment (baseline assessment) to after completing treatment (anticipated to be about 7 weeks after starting treatment)

Secondary outcomes

  1. Feasibility of implementation

    number of patients who agree to join the group and attendance

    Time frame: From patient recruitment until study ends (anticipated to be about 6 months after recruitment begins)

  2. Treatment fidelity

    Session fidelity to the CLCO-9 treatment program (per session fidelity checklists)

    Time frame: Measures after each session for the duration of treatment offered as part of the study (anticipated: about 6 months from recruitment start to study end)

  3. Client Satisfaction Questionnare-8

    Patient satisfaction

    Time frame: After each session for the duration of treatment offered during the study (anticipated to be about 6 months)

  4. Broset Violence Checklist scores

    Behavioral indicator documented in patient chart as a staff-rated indicator of imminent patient violence (only available if patient gives permission for chart review)

    Time frame: One month before starting treatment to after completing study, which is anticipated to be about 7 weeks after baseline (e.g., after completing post-treatment assessments or discharge, whichever comes first).

  5. Patient restraint/seclusion events

    Behavioral indicator documented in patient chart of instances that patient was restrained/secluded during current hospitalization (only available if patient gives permission for chart review)

    Time frame: One month before starting treatment to after completing study, which is anticipated to be about 7 weeks after baseline (e.g., after completing post-treatment assessments or discharge, whichever comes first).

  6. Patient engagement in other treatment meetings/groups

    Behavioral indicator documented in patient chart of patient's engagement in treatment meetings and groups beyond the CLCO-9 group during the current hospitalization (only available if patient gives permission for chart review)

    Time frame: One month before starting treatment to after completing study, which is anticipated to be about 7 weeks after baseline (e.g., after completing post-treatment assessments or discharge, whichever comes first).

07

Study locations

1 of 1 sites recruiting
  • Worcester Recovery Center and Hospital
    Worcester, Massachusetts 02451, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — We do not have a plan to share individual participant data with other researchers.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for May 2027, 14 months after the start.

Of 460 non-industry interventional studies with no phase under Psychotic Disorders, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's planned 14 months is below that.

Counting every sponsor, half of 462 studies reached it within 34 months; a quarter within 19 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2026
First posted
Jan 22, 2026
StartActual
Feb 5, 2026
Primary completionEst.
May 1, 2027
CompletionEst.
May 1, 2027
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07359157
Collaborators
Worcester Recovery Center and Hospital
Responsible party
Faith Scanlon (Counseling Psychologist, Instructor of Psychology, Massachusetts General Hospital) — Principal investigator
First posted
Jan 22, 2026
Start date
Feb 5, 2026
Primary completion
May 1, 2027 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Aug 12, 2026

Study contacts

Faith Scanlon, PhD
Contact
fscanlon@mgh.harvard.edu
6177242079
Corinne Cather, PhD
Contact
CCATHER@mgh.harvard.edu
6177266692
Faith Scanlon, PhD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion